Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

New insight into how emphysema and COPD develop

By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develop.

14 Oct 2011

Cigarette smoke interferes with Cystic Fibrosis Transmembrane Conductance Regulator protein

If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think. A new research report appearing online in the FASEB Journal shows that smoking cigarettes affects the lungs in a way that is very similar to cystic fibrosis, a life threatening disease affecting the lungs and other organs.

13 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011

Patients with chronic conditions likely to change their preferences for CPR

Patients with chronic conditions are likely to change their preferences for receiving emergency procedures in the event of cardiac arrest, according to new findings.

27 Sep 2011

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory Society.

27 Sep 2011

Novartis files marketing authorisation with EMA for NVA237 to treat COPD

Sosei Group Corporation, today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri Breezhaler, triggering a $5m milestone payment to Sosei.

27 Sep 2011

Study: Underweight COPD patients more likely to face death

Patients suffering from chronic obstructive pulmonary disease (COPD) are at a higher risk of death if they are underweight.

27 Sep 2011

Men over 75 with prostate cancer are being undertreated: Study

It's an ongoing debate: Should men over a certain age be treated for prostate cancer? Should these patients be submitted to treatments that may result in significant side effects if they may not live very much longer?

27 Sep 2011

People with COPD, reduced lung function more likely to develop cardiovascular disease

A new study has shown that people with chronic obstructive pulmonary disease (COPD) or people with reduced lung function are at a serious risk of developing cardiovascular disease.

26 Sep 2011

Social and economic impact of COPD on working population

New research has revealed the devastating personal and financial impact that chronic obstructive pulmonary disease (COPD) can have on the working population.

26 Sep 2011

Scientists identify genetic variants associated with lung health

Scientists have for the first time discovered sixteen new sections of the genetic code that relate to lung health -- opening up the possibility for better prevention as well as treatment for lung diseases.

26 Sep 2011

Study finds link between increased respiratory symptoms and lower altitude areas of river valleys

The research will be presented tomorrow at the European Respiratory Society's (ERS) Annual Congress in Amsterdam. The ERS Congress will officially open today. In the first study of its kind, researchers from the UK aimed to assess the impact of weather, pollution and geography on the symptoms of people with chronic obstructive pulmonary disease.

26 Sep 2011

Levosimendan may effectively improve muscle function in patients with respiratory failure

Treatment with the calcium-sensitizing drug levosimendan may be effective in improving muscle function in patients with respiratory muscle weakness, which often accompanies chronic diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure, according to researchers in the Netherlands, who studied the effects of the drug on healthy volunteers.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

New Poll: 9 out of 10 Ontarians would support an investment in lung health

According to a new Leger Marketing poll conducted for the Ontario Lung Association, 9 out of 10 of Ontarians would support the Ontario government investing in lung health today if it would save future healthcare spending.

22 Sep 2011

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

21 Sep 2011

Study finds high prevalence of cigar use among young adults and minorities

A new study in October issue of the American Journal of Public Health measures brand usage trends and the prevalence of cigar use among specific populations.

20 Sep 2011

AHRQ: Hospital readmissions comparatively higher among black COPD patients

For patients age 40 and over with chronic obstructive pulmonary disease (COPD), hospital readmissions within 30 days of initial treatment were 30 percent higher among blacks than Hispanics or Asians and Pacific Islanders and about 9 percent higher than whites in 2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

17 Sep 2011

Taiwan residents to receive two month free access to The Cochrane Library

Taiwan residents will receive free access to The Cochrane Library in August and September 2011, in collaboration with the Taiwan Evidence Based Medicine Association at their Annual Conferencein September, whereDr. Charles Young, VP and Publishing Director for Global Clinical Solutions, atThe Cochrane Library's publisher, Wiley-Blackwell, will be presenting a session.

12 Sep 2011

Non-communicable disease epidemic a global problem

Later this month the United Nations will convene a high-level meeting on non-communicable diseases. The world's global health news has been so dominated by infectious culprits - HIV/AIDS, malaria, tuberculosis, influenza - that it's easy to forget just how big a toll conditions like diabetes, cancer and heart and lung disease take say experts.

9 Sep 2011